Dan Gasby

home / authors / dan-gasby

Articles

October 20th 2021

The Promising Future of Alzheimer Disease Treatment

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Panelists conclude the discussion with personal insight into the promising future of Alzheimer disease treatment.

October 18th 2021

Disease-Modifying Therapy: Defining Response

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Expert panelists consider how to define response to disease-modifying therapies and discuss the threshold for treatment ineligibility due to lack of response.

October 13th 2021

The American Brain Foundation: Driving AD Treatment Development

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

A member of the American Brain Foundation discusses the organization’s role in the development of Alzheimer disease management and improvement in education.

October 11th 2021

Offsetting the Increased Cost of AD Treatment

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Key opinion leaders discuss possible ways to mitigate the increased cost of Alzheimer disease treatment.

October 6th 2021

Stratifying Patients for Treatment Eligibility

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

A discussion on the stratification of patient populations for treatment eligibility based on various decision factors.

October 4th 2021

Developing Policies for Early Biomarker Detection

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Panelists discuss how to craft future policies for early biomarker detection to use developing therapies that target underlying pathophysiology.

September 29th 2021

Improving Access to Appropriate AD Care

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Key opinion leaders consider effective ways to improve access to appropriate care for individuals with Alzheimer disease.

September 27th 2021

Improved Tracking of AD Comorbidities and Progression

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Expert panelists discuss methods to better monitor comorbidities and adverse effects associated with Alzheimer disease.

September 22nd 2021

Goals of AD Therapy With Early Detection

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Experts in the management of Alzheimer disease consider the future goals of therapy in tandem with the development of early detection polices.

September 20th 2021

Diagnostic Process for Individuals With Suspected AD

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

A discussion on the typical journey of a patient with Alzheimer disease from initial presentation to proper diagnosis within the health care system.

September 15th 2021

Key Drivers for Health Care Utilization and Spending

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Key opinion leaders discuss which factors contribute to patients and caregivers deciding to seek health care guidance and assistance for Alzheimer disease.

September 13th 2021

Health Inequities Among Patient Populations With AD

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

A discussion on the disparity in access to quality health care between various patient populations.

September 8th 2021

Increased Prevalence of Alzheimer Disease

Neil B. Minkoff, MD Mona Chitre, PharmD Michael Cantor, MD Richard Isaacson, MD Dan Gasby

Experts in the management of Alzheimer disease consider the increased prevalence of Alzheimer disease in the United States with growing geriatric populations and how the health care system is adapting.